
Publikationen von C. Farina
Alle Typen
Zeitschriftenartikel (14)
2008
Zeitschriftenartikel
197 (2), S. 128 - 139 (2008)
BDNF and its receptors in human myasthenic thymus: Implications for cell fate in thymic pathology. Journal of Neuroimmunology 2007
Zeitschriftenartikel
28 (3), S. 138 - 145 (2007)
Astrocytes are active players in cerebral innate immunity. Trends in Immunology
Zeitschriftenartikel
190 (1-2), S. 72 - 79 (2007)
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. Journal of Neuroimmunology 2006
Zeitschriftenartikel
129, S. 200 - 211 (2006)
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2005
Zeitschriftenartikel
159 (1-2), S. 12 - 19 (2005)
Preferential expression and function of Toll-like receptor 3 in human astrocytes. Journal of Neuroimmunology
Zeitschriftenartikel
4 (9), S. 567 - 575 (2005)
Glatiramer acetate in multiple sclerosis: Update on potential mechanisms of action. Lancet Neurology
Zeitschriftenartikel
64 (8), S. 1481 - 1482 (2005)
Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology
Zeitschriftenartikel
58 (1), S. 110 - 111 (2005)
Differential expression of CD150 (SLAM) on monocytes and macrophages in chronic inflammatory contexts: Abundant in Crohn's disease, but not in multiple sclerosis. Journal of Clinical Pathology 2004
Zeitschriftenartikel
16 (6), S. 799 - 809 (2004)
Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. International Immunology
Zeitschriftenartikel
127, S. 1370 - 1378 (2004)
Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2002
Zeitschriftenartikel
123 (1-2), S. 188 - 192 (2002)
Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. Journal of Neuroimmunology
Zeitschriftenartikel
249 (11), S. 1587 - 1592 (2002)
Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis - A pilot study. Journal of Neurology
Zeitschriftenartikel
73 (4), S. 321 - 331 (2002)
Treatment of multiple sclerosis with glatiramer acetate - new information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies. Nervenarzt 2001
Zeitschriftenartikel
124, S. 705 - 719 (2001)
Treatment of multiple sclerosis with Copaxone (COP) Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain